01-2012

Beware  of Hepatitis B at the nail salon
Pakistan  Arrests Pharma Execs Over Patient
Deaths
J&J  Must Face Lawsuits Over OTC Motrin Labeling

Curing
HCV For Many Coming   
FDA  Warnings Not Heeded Equally
Many High-Risk Americans Don't Get Hepatitis B
  Vaccine
Teens  Lacking in Protection Against Hepatitis
A
Uninformed  Consent: Average Study Participant Likely Unaware of
Risks
Editorial-How  to Optimize Treatment of Hepatitis C

Pot-based  prescription drug looks for FDA OK
New  Hepatitis C Regimen Stimulates Changes in Therapy
Management
New Combo  KOs HCV Without Interferon,
Ribavirin
Boceprevir  and telaprevir for hepatitis C: safety management in
clinical practice
Dermatological  side effects of hepatitis C and its treatment:
Patient management in the era of  direct-acting
antivirals

Scientists have now identified  a
potential new method to block the lifecycle of the Hepatitis C virus, which
  could lead to new therapies for those affected by the disease.

Hepatitis C Requires Fat to Replicate:
The
  Center for the Biology of Chronic Disease has recently learned that according
to  a new study published in PLoS Pathogens , Hepatitis C is one of a number of
  viruses that require fat to replicate in  the human body. View the full study
published in PLos  here on the web site.

Impact  of IL28B-Related Single Nucleotide
Polymorphisms on Liver  Histopathology in Chronic Hepatitis C Genotype 2 and
  3

2012  Stem Cell News and Research


From The Journal of
  Hepatology
Volume  56, Issue 2
Comparison  of Three Algorithms of Non-invasive Markers of
Fibrosis in Chronic Hepatitis C
CVS  Caremark Defrauded Medicare Part D: Auditor

U-M News: Kidney  failure risk higher for
liver transplant patients following policy  change
Study  reveals origins of esophageal cancer
THE  END OF THE BEGINNING FOR HEPATITIS C
TREATMENT
Treatment  and follow up of children with chronic hepatitis C in
Albania
.Morning  HCV News Ticker:Walgreen Overcharging For Generics
?
International  Symposium "Stem Cells and Human Liver Disease" -
Paris, France
A  widow died on the operating table when an experienced surgeon
tried to remove a  liver instead of a kidney in a fatal mix-up, an inquest heard
today.
Dangers of Hair  Salons
Pharma  Pays A Premium For Its Shopping Spree
Vitamin  D supplementation improves sustained virologic response
in chronic hepatitis C  (genotype 1)-naïve patients
CROs  Blast New Clinical Trial Rules In India
All  About; Incivek (Telaprevir)-An Oral Protease Inhibitor for
Hepatitis C Virus  Infection
Hepatitis  C - Five Ways You Can Take Care of Your
Liver
New  Target and FDA-Approved Cholesterol-Lowering Drug
Identified for HCV Therapy
No  link yet between hepatitis B, C cases and Ottawa
clinic
Future  treatment of patients with Hepatitis C
cirrhosis-2012
Triple  therapy for Hepatitis C geno1: telaprevir or
boceprevir?
The  future for the treatment of genotype 4 chronic hepatitis
C
Treatment  of patients with genotype 3 chronic hepatitis C-
current and future  therapies
PSI-7977-Whats  New In Treating Genotype 2 Hepatitis C
Patients
Treating Liver Cancer  With Antisense
Oligonucleotide
Low Vitamin D Levels  Linked To Depression, UT Southwestern
Psychiatrists Report
Merck CEO Frazier: "The future of the
industry is going to be more  partnerships"
Merck spinout nails promising study on hep
C vaccine
Hepatitis  C and Liver Health-Getting It Right In
2012
MicroRNA  Blood Test May Help Diagnose Early Liver Cancer in
People with Hepatitis B
Virus-triggered Autophagy in  Viral Hepatitis
Blood
tests and  transient elastography for liver fibrosis in chronic Hep C

Why  Have Cases of Liver Cancer Tripled?
ACH-1625  Protease Inhibitor Receives Fast Track For The
Treatment Of HCV
Results:CF102  in the treatment of hepatocellular carcinoma
(HCC).
Hepatitis  C (DAA) drugs - The invaders and the
barrier
Touching  some firm ground in the epidemiology of NASH -
editorial   
Financial  Support
Important  updates to PegIntron labeling      
The  Patient With Cirrhosis: Don't Miss This
How Should I  Approach Elevated Liver Enzymes?
Umbilical Hernia  Repair in Patients With Liver
Cirrhosis
Hepatitis  C - Looking Ahead to 2012
Cacopardo  B, Camma  C, Petta  S, Pinzone  MR, Cappellani  A, Zanghi  A, Nicolosi  A, Nunnari  G.
Putting  Fish Oil to the Test
Scientists Examine  Toxicity Of Medicinal Plants In
Peru

12-2011

Liver:  Stem Cell Updates and News 2011
Hep
C Nukes/Drug Development
14  Physicians Accused of Kickbacks for Imaging
Referrals
Police arrested  Orange Community MRI Executive Director
Chirag Patel, as well, for allegedly  paying a total of $51,500 in kickbacks to
physicians... continue  reading..
Safety Assessment Of  Botanical Ingredients Of Concern
In Plant Food Supplements
New  HCV Clinical Trial To Evaluate Merck’s-VICTRELIS
with Roche's Mericitabine Plus  SOCexperimental  Hepatitis C Drug PSI-938 Halted In Clinical
Trial
A  20-year cohort study on the natural history of untreated HCV
infection in rural  Chinese plasmaphoresis
donors
Hepatitis C-Impact of age > 65  years on svr
and relapse
Impact  of age more then 65 years on svr and relapse in chronic
hepatitis c (chc)  patients (pts) treated with peginterferon alfa-2a (40kd)
(pegifn?2a[40kd]) plus  ribavirin (rbv): final analysis from the large
multinational real-world  prophesys cohorts
Hepatitis C  treatment – Clearing the
mind
Liver-induced  inflammation hurts the
brain
Hepatitis  News Ticker- Telaprevir and
Boceprevir
New In  Mulimedia
Podcast:
Interferon-Free Treatment Regimens for  Hepatitis C: Are We
There Yet?
Podcast:
Advanced Liver  Disease Volume
19 Issue 3 August/September 2011
Advanced  Liver Disease: What Every Hepatitis C Virus Treater
Should  Know
Identification and treatment of advanced hepatitis C
virus (HCV)  infection is often challenging. Accurate fibrosis staging can be
performed only  by liver biopsy. For patients with advanced fibrosis (Metavir
score, F3 or F4),  progression to decompensated liver disease occurs at a rate
of approximately 5%  per year and progression to hepatocellular carcinoma occurs
at a rate of 1% to  2% per year.
Video:Marlene
Pig-Induced  Pluripotent Stem Cells May Be Safer Than Previously
Thought
BI  201335-Boehringer announced final patient entry for Phase
III Trial
Boehringer  hep C programme makes advances
Of
Interest
Case Report Herpes Simplex  Virus Hepatitis in an
Immunocompetent Adult: A Fatal Outcome due to Liver  Failure
We
present the case of a previously healthy 41-year-old female  who developed
herpes simplex virus hepatitis leading to fulminant liver failure  and death.
Antemortem diagnosis of this disease is often difficult, and, as a  result
proper treatment is delayed. The aim of this paper is to review this rare  but
important cause of liver failure, its clinical presentation, and available
  treatment options.
The influence  of interferon alpha on the induction of
autoimmune thyroiditis in patients  treated for chronic viral hepatitis type
C.
HepDART  2011
Kauai, HI USA
December 4, 2011 -
December 8, 2011
The focus  of HEP DART 2011 is to assemble clinicians,
researchers and basic scientists  together to advance our knowledge of the
ongoing drug development processes in  the treatment of hepatitis B and
hepatitis C and other viruses affecting the  liver, including co-infections with
HIV. HEP DART 2011 will uniquely blend the  areas of biology, chemistry,
pharmacology and clinical research to provide the  scientific community with an
increased understanding of the current and future  challenges in therapeutics
for hepatitis infection
HepDART Coverage @ NATAP
HepDART: REAL-LIFE SAFETY OF  TELAPREVIR OR BOCEPREVIR IN COMBINATION
WITH PEGINTERFERON ALFA/RIBAVIRIN, IN  CIRRHOTIC NON RESPONDERS. FIRST RESULTS
OF THE FRENCH EARLY ACCESS PROGRAM (ANRS  CO20-CUPIC)
(12/08/11
HepDART:
Characterization of  Virologic Resistance in HCV Genotype 1 Null
Responders Receiving a Dual Direct-  Acting Antiviral Combination of NS3
Protease Inhibitor Asunaprevir (ASV;  BMS-650032) and NS5A Replication Complex
Inhibitor Daclatasvir (DCV; BMS-790052)  (poster presentation)
(12/08/11)
View all coverage @ NATAP
Diabetes  Meds, Pancreatitis & Prescribing Habits

Hepatitis  C Medicines Save Lives in Cambodia
CDC's  proposed guidelines for transplants say two sex partners
is too many for  top-notch organ donors
New In Multimedia
Hepatitis C Virus Vertical Transmission
BMS  and Tibotec plan all-oral hepatitis C regimen

Hepatitis  C- ACH-2928: Preliminary Phase 1b Proof-of-Concept
Data
Plasma-based  treatment goes viral
American  Society of Clinical Oncology issues annual report on
progress against  cancer
Transplant  candidates seek best quality livers, even if it
means waiting longer
Medivir - TMC435 will be  evaluated in a phase II combination
study with daclatasvir (BMS 790052) for HCV  genotype-1
patients
Under the agreement the companies will evaluate the
  potential to achieve sustained viral response 12 and 24 weeks post treatment in
  patients with HCV genotype 1 in a study with three treatment regimens:
-An
  oral, once-daily treatment regimen of daclatasvir and TMC435 with
  pegylated-interferon alpha plus ribavirin
2-An oral, once-daily treatment
  regimen of daclatasvir and TMC435 with ribavirin
3-An oral, once-daily
  treatment regimen of daclatasvir and TMC435 alone
Studies of patients with cirrhosis uncover  limitations
in liver cancer screening
Green tea flavonoid may prevent reinfection  with
hepatitis C virus following liver transplantation
Regulatory T-Cell Responses to  Low-Dose Interleukin-2
in HCV-Induced Vasculitis
Novel Hep C Treatment Excludes  Peginterferon
Alfa
Boceprevir  Often Successful as Rescue Treatment in
HCVReally?  The Claim: Coffee Can Prevent Some Medications From
  Working
AASLD-
The Liver Meeting® 2011  Educational Webcast of selected
sessions
If you haven't yet explored the  "LiverLearning" section
available @ the AASLD web site you're missing out on the  November meeting
webcasts, video podcasts, abstracts and more. Free registration  is required,
it's quick and painless folks, start the process by clicking Here.
Once  that is accomplished, check out some
of the topics and programs available below  .
View Complete list of selected
sessions by clicking here
Access -50  Webcasts ,783  ePosters ,1229  Abstracts ,50  Video Podcasts,31  PPT Shared Files at LiverLearning
New  Treatment Paradigms
by David R. Nelson

2011-11-07
Preparing  the HCV Patient for Treatment
by Andrew
Muir
2011-11-07
How  direct-acting antivirals (DAA) Work and Their
Limitations
by Raymond  Chung
2011-11-07
Hepatitis  Debrief
Dr. Gregory Everson
75
slide(s) – English
2011-11-08
Complications of  Cirrhosis
HCV: Diagnosis and Natural History
- 23 posters(s)
A  20-year cohort study on the natural history of untreated hcv
infection in rural  chinese plasmaphoresis donors
Jinyu Ren

2011-11-04
View Complete List of  selected sessions
Free registration
required
Register Here


11-2011
Neglect,  ignorance raise HCV infection in Vietnam 

Robin  Gibb Looks at 'Spider Medicine' for Liver Cancer, Sources
Say
Association  between Chronic Viral Hepatitis Infection and
Breast Cancer Risk: a Nationwide  Population-based Case-control
Study
Hepatitis C virus (HCV)  testing and diagnosis
Milk  Thistle Bolsters HCV Treatment
Four Star  Import & Distribution Inc. Issues An Alert On
Uneviscerated Fish
Living  with chronic illness during the holiday
season
Glassing  attack leaves sportsman with hepatitis

May  I Be Frank: A Life-Changing Documentary

Ontario  first province to reimburse new chronic hepatitis C
treatment VICTRELIS™ Now  Available for Eligible Patients in
Ontario
Pharmasset Shows  Inhibitex-to-Achillion Drugmakers Up for
Grabs: Real M&A
Full story:
Bloomberg
Treatment Update
Source- CCO
The  Beckoning Future: How Hepatitis C Drugs in Development May
Affect Practice Today  and Tomorrow
Review the current benefits
and limitations with protease  inhibitor-based HCV therapies, and the emerging
data on potential future  regimens and the advances they represent.
The  New Elements of HCV Care: Practical Skills to Optimize
Protease Inhibitor–Based  Therapy
HCV Genotypes  and new possible therapies
Investigational drugs in the treatment of  genotype
4
Telaprevir Reduces  Duration of Standard Treatment for Hepatitis
C by Half 24-week Telaprevir-based  Therapy Noninferior To 48-week Therapy, With
Fewer Adverse Events
VIDEO-Hepatitis C : Protease  Inhibitor BI 201335, Polymerase
Inhibitor BI 207127 and Ribavirin
More  hospitals offering complementary medicine
Patients'
expectations  and success criteria for liver transplants FDA  Debars Doc In Pfizer Research Scandal
J&J  And Gilead Expand HIV Cocktail
Partnership
Pharmasset Upbeat on Drug for  Resistant Hep C Strain:
CEO
The American Association for the Study of  Liver Diseases
November 2011 Annual Meeting
Today's AASLD  Updates
AASLD  Coverage Available On The Web Site
This
AASLD Summary attempts to  present recent data in an accessible format providing
a greater understanding of  current and future gentler HCV therapies that could
be available in the near  future.
Included are many of the investigational
second-generation protease  inhibitors and Interferon-free treatment regimens
presented at this months  meeting.
AASLD-Telaprevir/Boceprevir  Cost?

Randomized,  Placebo-Controlled Trial of Oral Silymarin (Milk Thistle) For
Chronic Hepatitis  C: Final Results of the SYNCH Multicenter Study

Comparative  Effectiveness of Hepatitis C
Treatment Adherence Interventions
New  contenders will duke it out with Vertex for the hep C crown
- FierceBiotech
The body's own surveillance system against
cancer
AASLD-BI  201335 plus BI 207127 and ribavirin-76% virological
response at week 12, and 59%  achieve SVR12 with 16 weeks
treatment
AsianWeek  partnered with San Francisco Hepatitis-based
organizations to raise awareness  about Hep B at the 4th annual Hep B Free
Gala
Monday  HCV News Ticker-Psychiatric Complications of Hepatitis C
Treatment
Pharmasset  Starts Phase 3 Trials of PSI-7977 Without
Interferon
Hepatitis C Transmission in  Injection Drug Users: Could Swabs
Be the Main Culprit? -
Does  the hepatitis c virus survive in dried
blood
AASLD-DEB025  potential interferon-free therapy/viral clearance
at six wks
Phase  2b PILLAR Study of Once-Daily TMC435
Interim  Data for VICTRELIS (boceprevir) in Prior Null
Responder
INCIVEK™  / VX-222-Interim Data Showed at 12wk 93%
SVR
Santaris  Phase 2a Data of Miravirsen Shows Dose-Dependent,
Prolonged Viral Reduction of  2-3 Logs HCV RNA After Four-Week
HCV/HIV  Incivek-Phase 2 Study Positive Interim
Results
PPI-461- Presidio Announces Proof-of-Concept Data And Initiation
of Clinical Testing For  PPI-668
INX-189  for Chronic Hepatitis C-Inhibitex Reports Corporate
Developments
Birth  cohort screening for hepatitis C is cost effective, could
save thousands of  lives each year
PSI-7977  and Daclatasvir (BMS-790052) 12 wk Interferon-Free Tx
Arms Added-Genotype  1
New 12 Week, Interferon-Free Treatment Arms
Added to All-Oral  Combination Study of PSI-7977 and Daclatasvir (BMS-790052)
for HCV Genotype  1
Vertex  Announces Recipients Of Special Grants Initiative To
Support People With  Hepatitis C
Excess liver-related  morbidity in treated chronic Hep C

Hepatology 2011: 54(5):
1547–1558
Liver Stiffness Diminishes  With Antiviral Response in
HCV A  new view of patient data: Using electronic medical records to
guide  treatment
Twitter  Stories: How social media saved one man’s
life
Amarillo Biosciences' Live Interview

FDA reports 35 innovative new drugs
approved in fiscal year  2011  From NATAP
Response-guided Telaprevir  Combination Treatment in Genotype 1
Chronic Hepatitis C Patients who had Prior  Relapse to Peginterferon
Alfa-2a/Ribavirin
Telaprevir in Combination  with Peginterferon Alfa-2a and
Ribavirin Increased Sustained Virologic Response  in Genotype 1 Chronic HCV

Health:  The ongoing battle to tackle hepatitis C

Pharmasset  All-Oral Therapy By 2013?
Pharmasset
  Announces the Initiation of an Interferon-Free Phase 3 Program with PSI-7977
for  HCV
ACG  2011: Dr. Ira Jacobson Discusses the Importance of the New
Protease Inhibitors  for HCV
[Podcast]


10-2011
A  Cure For Hepatitis C-The Pharmaceutical Companies and
Us
This review  covers the newly approved HCV protease inhibitors
boceprevir and telaprevir,  along with the promise of interferon free
therapies.
Hepatitis  News Ticker; New procedure for liver cancer
treatment
Vertex  Initiates Phase 3b CONCISE-Study Incivek
w-peg/riba
Vertex  Pharmaceuticals Incorporated today announced
the initiation of a Phase 3b study  called CONCISE that will evaluate the
potential for treatment with INCIVEK™  (telaprevir) combination therapy to be
shortened to 12 weeks in people with  genotype 1 chronic hepatitis C who have
the ‘CC' variation near the IL28B gene.
Clinical Trials

To learn more about Hepatitis C virus  clinical trials or to find
out if a study is enrolling patients in your area,  please click  here.
Recent  October Updates On Hepatitis C Research
Liver  Health and Wellness
New In
Multimedia;  Videos and  Podcasts
About  Hepatitis C in Canada
New In Liver
Cancer  Updates;
European studies on risks of  hepatocellular
carcinoma
Radiology Studies On Yttrium-90  Radioembolization

Unsafe Needles Pose Major Health Risk to
Doctors, Nurses
Biotech Stock Mailbag: Idenix vs.
  Pharmasset?
Boceprevir based therapy cleared the
hepatitis C  virus in 70 percent...Full story: Drugs.com
TGIF-Hepatitis  News Ticker; New drug boosts hepatitis
treatment
Stem  cells in the media today: the good and the
ugly
Chronic Hepatitis C in  Children
DEBO25 vs Boceprevir New  Study in African-Americans
-
Roche Buys U.S.-Based Anadys in
Bid to Boost Hepatitis  Franchise
From Natap;
ANA-598
HCV Non-Nuke Phase 2b  Study Preliminary Data Results Background to Phase IIb
Study - (10/14/11)
HCV  News Ticker-Interferon Free RegimenTo Treat Hepatitis C
?
These days we  dare to dream of an interferon free combination
to treat hepatitis C. Could it  happen? Enter; an all oral regimen, consisting
of a few pills, a better cure  rate, and less side effects
The Alcohol And Harm  Link Is Stronger In Estonia, Latvia,
Lithuania, And Sweden Than In  Italy
Hey  Doc, Victrelis-boceprevir or
Incivek-telaprevir?
Achillion  counts another hep C
milestone
Anadys  Positive 12-Wk Data for Setrobuvir in Phase 2b Hepatitis
C Study
Hepatitis C News Ticker; Galectin
Announces New Data-Treatment of  Fatty Liver Disease and
Fibrosis--
INCIVEK(TM)  (telaprevir) Now Available in Canada

Transgene Says 3 Patients in Hepatitis
Trial Had Blood  Disorders
Stem Cell Updates;
Scientists turn liver  cells directly into
neurons with new technique
Fully mature liver cells  from
laboratory mice have been transformed directly into functional neurons by
  researchers at the Stanford
  University School of Medicine. The switch was accomplished with the
  introduction of just three genes and did not require the cells to first enter a
  pluripotent state. It is the first time that cells have been shown to leapfrog
  from one fundamentally different tissue type to another.
New Transplant Method  May Eliminate Need
for Lifelong Medication
ELECTRON  Trial - Pharmasset Adds New Study
Arm-PSI-7977
Biotron  Soars on Results for Hepatitis C Drug

Seeking  superior stem cells
Certain  dietary supplements associated with increased risk of
death in older  women
Hepatitis C Case Study at Prosperity
Specialty Pharmacy
Big  News In Todays Hepatitis News Ticker
HCV  News Ticker; Hepatitis C Virus May Increase The Risk Of
Brain Disorders And  Death In People With HIV
Undercounted Populations Raise Estimate of
True U.S. Hepatitis C  Prevalence
Interferon  Free Combo-PSI-7977/riba"Two HCV Meds are Better
than One For Pharmasset  "
Hepatitis  C Support-Newsletters, And Forums
Inhbitex
nucleotide in Phase  2 -
New  York Stem Cell Foundation researchers create human stem
cell lines from  SCNT
Influenza vaccination in  the organ transplant
recipient
Research Avenues  Suggested For Treating Excess Fat Storage And
Obesity
AASLD-protease  inhibitor BI 201335 and polymerase inhibitor BI
207127 Interferon Free Combo-New  Data to be presented by
Boehringer
AASLD-Santaris  Pharma to Report New Clinical Data From
Miravirsen Phase 2a Study to Treat  Hepatitis C Naturally Occurring Genotype 2b/1a
Hepatitis C Virus in the United  States
Monday  Hepatitis C News Ticker
Help, How Do I Take Incivek  ?
Video-Side  Effects Of Hepatitis C Treatment Oct
2011
HCV-Listeria  Outbreaks, Tainted wipes; Its
Personal

09-2011
Pharmasset impresses with oral HepC
treatment
AASLD  Updates
T.G.I.F  Hepatitis News Ticker; Hep C Drugs:Bristol-Myers, Merck
and Vertex
Hepatitis  C patients likely to falter in adherence to treatment
regimen over  time
2011 practice guideline  by the American Association for the
Study of Liver Diseases
Hepatitis  C virus resistance to protease inhibitors

Hepatitis
C virus infection  in USA: an estimate of true prevalence - 'estimated 5.2 to
7.1 million HCV+ in  USA'
When  It Comes To Pain Relief, One Size Doesn't Fit
All
Hepatitis C Side Effect Management:  Lauren Thomas, RN, NP-C
with Liver Specialists of Texas
Hepatitis C News TIcker
Different
Fruits And  Vegetables Affect Cancer Risk In Different Parts Of
Bowel
Arm  Yourself Against Colds and Flu This Fall
Recruiting  A Study to Evaluate the Efficacy, Safety, and
Pharmacokinetics of ABT-450 With  Ritonavir (ABT-450/r) When Given Together With
ABT-333 and Ribavirin (RBV) in  Treatment-Naïve and Non-responder Subjects With
Genotype 1 Chronic Hepatitis C  Virus (HCV) Infection
Treating liver cancer
Tainted  Transplants
Roche  cleared over rep conduct complaint
OSHA  Fact Sheet: Protecting Yourself When Handling Contaminated
Sharps
Heroin Task Force hears Hepatitis C
report
How  are the different types of hepatitis
transmitted?
Serum markers for necroinflammatory
activity in patients with  chronic viral hepatitis and normal or mildly elevated
aminotransferase  levels
Marijuana  Extract Might Help Prevent Chemotherapy-Related Nerve
Pain
Vegas  doctor tied to hepatitis C cases called competent for
trial
UPDATE 2-EU agency calls for restrictions
on Sanofi's  Multaq
Hepatitis  C: current management and emerging
therapies
Surgeons Object to New CDC Organ-Screening
Guidelines
Bedbug  Solution May Be More Harmful than Problem
(CME/CE)
French judges probe maker of discredited
pill
Europeans  looking again at orlistat and
liver injury
European  approval for hepatitis C drug, Telaprevir-Incivek
"called Incivo in Europe."
Signs  of Poor Digestion-Bowel Problems
How  our Liver kills "killer cells"
Inhibitex
  Commences Dosing of Phase 2 Clinical Trial of INX-189 in HCV Infected Genotype
  2/3 Patients
BMS-790052-Positive  results from a Phase II trial "83% SVR in
24wks"
CGH Podcast September 2011: Immune
Dysfunction and Infections in  Patients With Cirrhosis
Pocket  Guide For Using
Telaprevir and
Boceprevir
Hepatitis  News Ticker- A Practical Guide for the Use of
Boceprevir and Telaprevir
Telaprevir-Shorter  treatment
Two-Thirds  of Hepatitis C Patients Can See a Cure in Half the
Time
Hepatitis  News Ticker
Pharmasset  Initiates  Interferon-Free Trial of PSI-7977 and
PSI-938 for All HCV Genotypes
Oral telaprevir  in previously untreated patients with hepatitis
C virus genotype 1  infection
Scientists a step closer to Hepatitis C
vaccine
Britain  abandons total ban on gay blood donations

Preliminary  Testing Of New Drug Against Hepatitis C Shows Good
Promise
HCV entry receptor as potential targets
for siRNA based inhibition  of HCV
Pharmasset  Announces 91% SVR12 From the PROTON Trial in
Subjects With Hepatitis C Genotype  1
Dramatic  Changes in Hepatitis C Treatment Expected to
Continue
Jennerex Presents Interim Clinical Data of
JX-594 Followed by  Sorafenib Demonstrating Tumor Responses in Liver
Cancer
The  Problem Of The Use Of Unproven Dietary
Supplements
Low doses of  acetylsalicylic acid increase risk of GI
bleeding
PEG-IFN and Ribavirin for  Patients With HCV Genotype
6a
Liver
Transplant Recipients  with Chronic Hepatitis C
Influenza  Vaccination in the U.S., 2011–2012
Walnuts
Reduce Breast  Cancer Risk By Half In Animal Studies
Metabolic Syndrome  Prevented By Powerful Antioxidant
Resveratrol In Lab Tests
Covalent Drugs Form Long-Lived Ties
Irreversible inhibitors may  provide unique benefits in drug development

Mild
Thyroid Dysfunction Does  Not Lead to Depression
Association  between lichen planus and Hepatitis
C
Fatigue, depression and chronic  hepatitis C infection.
Full story: CiteULike
Unusual  Swine Flu Cases Have H1N1 Links
Cirrhosis  screening for liver  cancer
Dean  Clinic Works To Notify Patients Of
Possible
Big  pharma has paid US doctors $150m already in
2011
Gilead  Amends Study Design for Ongoing Hepatitis C Clinical
Trials That Include GS  9190, Pegylated Interferon and Ribavirin, and Another
Direct-Acting Antiviral  Agent
Should  The US Compensate Injured Trial
Patients?
Hepatitis  C Neuropsychiatric symptoms-“brain fog”

Telaprevir-Incivek/Boceprevir-Victrelis-Paying  For Hepatitis C
Treatment
Study  Suggests HCC Resection Superior to
Transplant
Two New Videos; Posted  in Multimedia
Trial  Supports Addition of Telaprevir for HCV Genotype 2

Early TIPS for  Ascites Study Seeks to Improve
Survival
Hepatitis  C; Type II Cryoglobulinemia
Blog; Sept  1 Hepatitis News Ticker
Doctor’s  Lawsuit Targets Parents of Patient Who
Overdosed


08-2011  News Digest
Aug
31

FDA  Request That H&P Recall Povidone Iodine Prep Solutions
W-other Multiple  brands affected
Update;
Beleaguered wipe-maker hires new COO;
prepares to reopen
Research  identifies marketing mix strategy for pharmaceutical
firms
TMC435  ;MedivirAB Completed Enrollment of Three Global Phase 3
Trials
Telaprevir  Markedly Improves HCV Genotype 1 Cure Rates

Pharma  Paid US Docs $150M So Far This Year
From
CCO
Direct-Acting  Antivirals in Treatment-Naive HCV
Patients
Recent  Advances in Antiretroviral Therapy
Nutritional  considerations in end-stage liver
disease
Treating  children with HCV
Neuromuscular Diseases Associated With
Chronic Hepatitis C Virus  Infection
Few  treatment options for growing population of drug users in
Af...
Google  CEO Knew About Illicit Online Pharmacy Ads

Drug Watch
Two New  Drugs for Chronic Hepatitis C
More From
Drug Watch @ AJN
New  Drug to Treat HIV Infection
New  Drug for Type 2 Diabetes
Ohio Increases Algae Advisory For Lake
Erie Beach
Recommended:  Stem Cell Blogs
Stem  cells: distinguishing hype and hope
Other  conditions associated with hepatitis C
virus
Full  HCV Text Articles
HCV  Resistance Testing - Launch of HCV GenoSure

Interferon  Free Combinations
PSI-938 Receives Fast Track
from the FDA for Hepatitis  C
Medical Advances: Wiping Out
Hepatitis C -- In Depth Doctor's  Interview
Full story: Ivanhoe
Drug
Rep Arrested For  Stealing Oxycodone From Pharmacy
HIV Linked to False Negative Hep C Results
Using Some Rapid  Assays
Health Canada  Okays INCIVEK For People With Hepatitis C

Related;Health Canada Clears  Victrelis-Boceprevir New Hepatitis
C Drug http://hepatitiscnewdrugs.blogspot.com/2011/08/health-canada-clears-victrelis.html
Popular herbal supplements may adversely
affect  chemotherapy treatment
Doctors,  Nurses Often Use Holistic Medicine for Themselves

Update; Check  out two new videos;
Patient Video; New HCV
New and  Resistance
And...
Telaprevir Alone or With Peginterferon and
Ribavirin  Reduces HCV RNA in Patients With Chronic Genotype 2 But Not Genotype
3  Infections
Metabolic  Syndrome May Cause Kidney Disease
Global
epidemiology of  hep B and hep C in people who inject drugs
Addiction:  All in the mind?
A  Chemically Sound Reason to Exercise with HCV

Two  Liver Cancer Discoveries May Impact Hepatitis
Patients
Treatment Action Group publishes Guide to
Clinical Trials for  People With Hepatitis C
Use of  New HCV Protease Inhibitors ‘Not That Simple’

Inciek/Victrelis;  New approvals may change treatment for
hepatitis C
Hepatitis  Digest;HCV abstract-BMS-790052, Liver Cancer,Vitamin
D and Diabetes
Listen;  New Drugs To Treat Hepatitis;Telaprevir/INCIVEK
and
Boceprevir/Vicrelis
FYI-Which  New Hepatitis C Drug do MDs Prefer? Incivek vs.
Victrelis
Over at FiercePharm.com is a free  report by Sermo on;
Which New Hepatitis C Drug do MDs
Prefer?
Incivek (telaprevir) vs.  Victrelis (boceprevir)
If you're
curious you can Click  Here and register to get the results.
Video;  Dr. Riad Salem discusses his manuscript
"Radiographic Response to Locoregional  Therapy in Hepatocellular Carcinoma
Predicts Patient Survival Time." Watch Video Here,  and View Abstract Here
Does  the information provided with herbal products available
over the counter enable  safe use?
Hepatitis  News Digest For Aug-11 2011
Don't
Miss; 2011Chronic  Hepatitis C-Full Text
More Successful  Transplants Following Out Of Body Experience
For Stem Cells
Hepatitis  C-New Protease Inhibitor (NS3/4A) Drug Resistance
Test
View Complete PDF  At NATAP
New  Protease Inhibitor (NS3/4A) Drug Resistance Test
-
Hepatitis C virus  influences neurocognitive function in
patients free from other risk factors
Merck  Gets Subpoena Related to Drug MRKT-Hepatitis C Drugs
PegIntron and Intron A
Erectile Function And  Libido Improve In Obese Diabetic Men Who
Lose Weight
Victrelis - New hepatitis C drug exciting -- but
expensive
Ground  Turkey Recall - Why The Five Month
Delay?
Going Viral:  New Hepatitis C Drugs Owe Their Success to
HIV
Retinopathy  associated with pegylated interferon and ribavirin
in patients with hepatitis  C
Hepatitis  C-Central hypothyroidism and relation with interferon
treatment
Boceprevir-Victrelis-Telaprevir  "INCIVEK" Which pegylated
interferon ?
Health  Canada Clears Victrelis-Boceprevir New Hepatitis C
Drug


07-2011 News Digest
Celsion Reaches Major Milestone With
Enrollment of 600th Patient  in Its Pivotal Phase III HEAT Study of ThermoDox(R)
in Primary Liver  Cancer
Counseling, Drug Treatment Can Increase
Hep C Treatment  Eligibility
OctoPlus tries to get drug-delivery
tentacles into  generics
Global HCV 150 Million:  reused syringes, IDU, sexual
transmission, HIV coinfection,  China/India/Pakistan, Africa -
Around 24,000 people die of
HCV
Simplified international  diagnostic criteria for acute-onset
autoimmune hepatitis
Boehringer  Offers ADAPs Rebates On HIV Meds
First  large study to find HIV epidemic among gays in the Middle
East
Hepatitis  News Ticker Updates For Aug 2
MSD  launches hepatitis C drug Victrelis-Boceprevir  in
UK
Boceprevir  response and resistance differs according to HCV
genotype 1 subtype
Hepatitis  News wrap-up for Sunday July 31
United Kingdom: Programs May Curb
Hepatitis C in Drug Users
New vaccine for hepatitis C
virus
Pharmasset Announces Final  SVR Data (100% 24/24) from PROTON
trial with PSI-7977 in Subjects Infected with  Hepatitis C Infection Genotype 2
or 3 - 12 weeks therapy -
World Hepatitis Day:  Call To Action
Nurse in Las Vegas hepatitis c trials
can't testify as expert  witness regarding cause
J&J cuts maximum Tylenol dose to
prevent overdoses
CBS Video;  Hepatitis C cure
Lilly aims to educate consumers on how
drug maker collaborates  with physicians
Nemesis List: Hepatitis C
Vertex Reports Second Quarter 2011
Financial Results and Provides  Updates on Launch of INCIVEKTM (telaprevir) and
Development Programs
Hepatitis  is not just a health issue

Nano-Sized
Drug  Transported Designed To Fight Disease
Music Legends Fight the Stigma of
Hepatitis C With New  Campaign
Four-Drug  Combo for HCV Shows Early Promise
Four  Drug Combo VX-222, INCIVEK, Peg/Riba: Interim results from
Vertex on their trial  deemed, ZENITH
The false distinction between basic and
applied science
Chronic Hepatitis C  Infection
Omega-3 Supplements May Lower
Anxiety
News;  Hepatitis Weekend Round-Up
CDC: Test HIV-infected men for hepatitis
C
Google  Health: Dead of Neglect
Hepatitis  C Drug Incivek (telaprevir); What are the side
effects ?
Hepatitis;Telaprevir,Disease  Progression and more in todays
news
Hep C Virus  Transmitted in Risky Gay Sex (CME/CE)

Genomics Researchers Shed New Light on
Inherited Traits.
Hepatitis  C Protease Inhibitors Bring New Options for
Patients
Study  suggests obesity accelerates progression of
cirrhosis
Metabolic  syndrome increases risk of both major types of
primary liver cancer
Natural  leukocyte interferon alpha (Alfaferone) combined with
ribavirin in the treatment  of patients with HCV-related
cirrhosis
U.S.:  Longtime Survivors or Newly Diagnosed, More Older Adults
Are Living With  HIV/AIDS
Hepatitis  C Transmitted by Unprotected Sex Between HIV-Infected
Men
Liver Transplant Video: An Inside  Look
New  Jersey Gov. Says Medical Marijuana Law Can Go
Forward
Tainted TPN Cases Put Focus on <797>
Rules
In case  you missed it;
Did  contaminated wipes give newborn baby lifelong brain
damage?
To read all  updates on the tainted wipes click  here
New effective therapies  for HCV are reshaping the standard of
care
Dynavax  Stock Plunges On Hepatitis B Study Results


Roche  Raises Profit Forecast As Cost Cutting Kicks
In

Pfizer  Facebook Page Is Hacked By Script Kiddies

Final  SVR results from Pharmasset's PSI-7977 phase 2b study in
HCV
Community-Based Primary  Care Treatment of HCV
Infection
Predicting Outcomes in Hep C  Vasculitis
Pitavastatin May Enhance  Antivirals in Some Hepatitis C
Patients
Obesity  Rate Is 30 Percent In 12 US States,
CDCReports

Is  pre-treatment liver biopsy necessary for all hepatitis C
genotypes?
VICTRELIS™  (boceprevir), Approved in the European Union for
Treatment of Chronic Hepatitis  C
Report: UPMC needs to up transplant
survival rate
Walgreens Specialty Pharmacy Drives
Adherence for Hepatitis C  Patients Through Therapy Management
Program
Hepatitis  Monday News; Abnormal liver tests in people 75 and
above assoc-with  mortality
Podcast  Dr. Galati; Liver Health -Tylenol safety, herbs and
alcohol.
Mayo   Podcast;
Lifestyle Changes Pay  Off in Non-Alcoholic Fatty Liver
Disease
FDA Reviewers Flag  Cancer Risk in Diabetes
Drug
Crack pipe sharing in B.C. shows gaps in
services for addicts:  researchers
'Humanized' Mice - A  New Way To Study Side Effects Of New Drugs
Before They Reach Clinical  Trials
‘Easy  to treat’ genotypes were not created equal: Can rapid
virological response (RVR)  level the playing field?
Gender  disparity and MELD in liver transplantation

Fighting  the bushfire in HCC trials
Shedding  new light on vitamin D and fatty liver
disease
Genomic  medicine reaches HCV-related liver transplantation:
Hopes and clinical and  public health implications
Hepatitis  C; Characterization of Serum Proteins Associated with
IL28B Genotype
‘Policy on tackling Hepatitis C outbreak
need of hour’
Telaprevir for Hepatitis C: Moving Toward
a Cure
Telaprevir,  boceprevir, cytochrome P450 and immunosuppressive
agents - A potentially lethal  cocktail (see article below editorial) -
Editorial -
The  unsolved mystery of kava toxicity
Meeting Report - 6th  International Workshop on Clinical
Pharmacology of Hepatitis Therapy (June  22-23, 2011, Boston, MA) FDA  approval signals more 'homework' on the horizon in
trials
News From The Journal  Of Clinical Investigation: July 11,
2011
PrEP
Reduces HIV Infections  Among Heterosexuals
Video; Fatty Liver Disease: Are You at Risk?

Hepatitis scare in Lab
west
Hepatitis  C Weekend Update; Clinical trials
Media reports of new hypertension study
should be taken with a  grain of salt
Two  Drug Companies Unite for All-Oral Hep C Regimen

Dose  of Reality on Alternative Stem Cell Treatments: What you
don’t know can hurt  you
http://www.ipscell.com/
Hepatitis  C News Digest;Experts find rogue stem cells in liver
cancer and Insulin  resistance was associated with a lower cure rate of patients
with Hep C
For More Of This Months News  See: HCV News
Digest
Interactive  map of cancer mortality risk
worldwide
What's New -- Part 2: Viral  Hepatitis in Children

This activity is a continuation of Part 1 which  discussed hepatitis A and B.
All  Oral Combo; Study to evaluate the combination of PSI-7977
and TMC435 with and  without ribavirin in prior null responder, genotype 1 HCV
patients
Medivir:  TMC435 has Received Fast Track Designation from the
FDA and TMC435 will be  studied in combination with Pharmasset's PSI-7977 for
HCV genotype-1
Non-alcoholic  fatty liver disease and non-alcoholic
steatohepatitis is increasing
Increased  incidence of hepatocellular carcinoma after diagnosis
of Hep B or C
New  Page On The Website
July podcast - Two
studies in the July issue of  Gastroenterology examine the relationship between
fruits, vegetables, folate,  and colorectal cancer
Simplified psychometric  evaluation for the diagnosis of minimal
hepatic encephalopathy
Adherence to  biopsy guidelines increases celiac disease
diagnosis
mpact of antiviral  therapy and long-term outcome of chronic
hepatitis C
VTE  burdensignificant in patients with cirrhosis

Hepatitis  C News Digest; FDA Probes New Death In Tainted Wipes
"Triad Prep Pads"
Scientists Fish For  Answers About Hepatocellular
Carcinoma
Ultrasound Guided  Liver Surgery Makes Tumour Removal
Safer
Other conditions associated with  hepatitis C virus
Really? The Claim: Hospital Mortality
Rates Rise in JulySyndromes  of Sjogren
Growth of hepatocellular  carcinoma in the regenerating
liver
For  Many Millions, Psoriasis Means
Misery
Diabetes  Mellitus Can Be Reversed By Severe
Diet
Predictor of sustained  virological response across genotypes in
HCV
HCV testing practices in  a high-risk urban ambulatory care
setting
The  global health burden of hepatitis C virus
infection
A  systematic review of hepatitis C virus epidemiology in Asia,
Australia and  Egypt
A  systematic review of hepatitis C virus epidemiology in
Europe, Canada and  Israel
Trends  and projections of hepatitis C virus epidemiology in
Latin America
Applying  a system approach to forecast the total hepatitis C
virus-infected population  size: model validation using US data 

Viral  Load Tied to Vertical Transmission of Hepatitis C

Emerging  therapies for hepatitis C offer a significant increase
in SVR and bring  treatment complexity
Gene Variant  Increases Fatty Liver Risk And Fibrosis
Progression
Cirrhosis risk score  predicts fibrosis progression in
HCV
Outcomes of adult living  donor liver transplantation

July 2011 Hepatitis Newsletters;
From  The hepc.bull - online  monthly newsletter (.pdf)

Click Here To Download ;2011 July/August
GI& HEPATOLOGY NEWS
Medical  Board Of Cailfornia
Hepatitis Monthly , July  2011 ,Volume: 11 Issue:
7
Liver Health Today
Click hereTo  Download
HCV Advocate
Download printable
version
In This Issue:
The  New HCV Epidemic?
Alan Franciscus,
Editor-in-Chief
Quick  Facts about the PI's
Alan Franciscus,
Editor-in-Chief
HealthWise:  Resisting Resistance
Lucinda K.
Porter, RN
HCV  Snapshots
Lucinda K. Porter, RN and Alan
Franciscus,  Editor-in-Chief
The  Next Wave(s)
Alan Franciscus,
Editor-in-Chief
More  Than Two-Thirds of Surveyed U.S. Clinicians Plan to
Prescribe Incivek and  Victrelis to Patients with Treatment-Naive Hepatitis C
Virus Genotype  1
Predictors of alcohol  use on liver function among young
HCV-infected injection drug users
Telaprevir  Improves Hepatitis C Treatment
Response
HCV Drug  TMC649128 Enters Phase 1b Trial
Entecavir  Effective for Hepatitis B Patients with Liver
Cancer
Host targeting cyclophilin  inhibitor alisporivir (DEB025)
presents a high barrier to resistance with no  cross-resistance to direct acting
antivirals, in Phase 3 Now -
Hepatitis-C  and its Effects on Liver Transplantation

Checking  up for Hep C and looking after yourself. Part
2
A rise in Hepatitis C is raising alarm
among health care officials  in Mercer County.
Telaprevir-Based  Regimens More Effective Than Current Standard
Of Treatment In Curing Genotype 1  HCV PatientsTelaprevir for Retreatment of  HCV Infection - NEJM
published
Telaprevir for Previously  Untreated Chronic Hepatitis C Virus
Infection -
Unmet Needs Among People  Reported With Hepatitis C, New York
City
Consumer Medication  Information: One Page Fits All

NEJM Study: New Drug  Represents Breakthrough In Treatment Of
Hepatitis C
New England Journal  Of Medicine Publishes Data From Two Phase 3
Studies Of INCIVEK™ (Telaprevir) In  Hepatitis C
Earlier Diagnosis Of  Liver
Cancer


06-2011
Vertex and Ahos Working together to bring
two new Hepatitis  C  Drugs To Patients
Noninvasive assessment of  liver fibrosis
HBV
& HCV Epidemics &  Screening in USA -
'Friday  HCV News;Telaprevir/Combination DAAs/Shortening Therapy
Duration
Starting Early Trials For New Cancer
Drug
Research  Team Tests Alternative Approach to Treating
Diabetes
BI201335  Shows Potent Activity against HCV
New  diabetes drugs go beyond insulin to flush out excess
sugar
Growth hormone may reduce pain and tender
points in  fibromyalgia
Why Incivek  and Victrelis Herald a New
Era in Hepatitis C Treatment
Reduced dose and duration of  peginterferon alfa-2b and
weight-based ribavirin in patients with genotype 2 and  3 chronic hepatitis C
-
Chronic
hepatitis C genotype  2 and 3: Are we ready for personalized medicine? (12-16
weeks therapy??) -
Infrared Systems International's
Subsidiary, AquaLiv, Inc.,  Strives to Be a Game Changer in Fight Against
HIV/AIDS
Reliability of liver  stiffness measurement in non-alcoholic
fatty liver disease
Boceprevir  vs. Telaprevir: What We Know and Don't
Know
Alnylam Presents  Phase I Data For ALN-VSP, An RNAi Therapeutic
For The Treatment Of Liver  Cancers, At ASCO Meeting
Paramedics  at risk from patients' body fluids: B.C. union
rep
2011-FDA  Transcripts Telaprevir/Boceprevir April Advisory
Committee Meeting
Jules  Levin From NATAP/Video - Hepatitis C Aging
Population
Newly  designed system of identifying molecules for treating
hepatitis C
New drug has city  woman free of hepatitis C
Interferon  Free Combinations
Merck to make donation to hepatitis
researchers
Host Mta1 Gene Is  Required For Optimal Survival Of Schistosome
Parasites, A Leading Global Cause  Of Cancer
Goodbye,  pyramid: USDA unveils MyPlate
Not all hospitals treat elderly the sameStudy finds hospitals need to measure quality of
care
Despite Prevention Efforts, HIV Infections
Reach 50,000 Every Year
'Doctor of Death' Jack Kevorkian is
dead
A Sustained Virologic  Response Reduces Risk of All-Cause
Mortality in Patients With Hepatitis C - pdf  attached
A
  Survey to Evaluate Evidence-Based Appraisal of New Therapies that will be used
  to plan future educational programs around DAAs.
Shorter Treatment for Acute Hep C Works in HIV-Coinfected
  MSM
Oral  combination therapy: future hepatitis C virus treatment?

Obesity Greater Risk  For Fatty Liver Than Moderate Amounts Of
Alcohol
Sanofi  Diabetes Drug Cuts Blood Sugar & Weight In
Study
Caffeine and Liver Disease in People
withHepatitis C
Two  New Drugs To Treat Hepatitis C And My Doctor

Longer Interferon Treatment Raises
Hepatitis C Cure Rate
Substandard  Hygiene Practices At Some VA
Hospitals
Filing for Social Security Disability on
Your Own
Long-term outcome of chronic hepatitis C
in a population-based  cohort and impact of antiviral therapy: a
propensity-adjusted analysis
Unexplained  Symptoms Eased By Acupuncture
Patients
With RA Or  Fibromyalgia Benefit From Yoga
Hepatitis  C Treatment; SVR is the goal, and humor is the rescue
drug.
New Drugs Encouraging  For African Americans With Hepatitis
C
Video/Vertex  Incivek Patient Steve Goodwin On
TelaprevirCharacteristics of Patients With
Nonalcoholic Steatohepatitis Who  Develop Hepatocellular Carcinoma
How
important is dark chocolate to a  well-balanced diet for promoting
health?
Potency,  safety, and pharmacokinetics of the NS3/4A protease
inhibitor BI201335 in  patients with chronic HCV genotype-1
infection
Treatment  of chronic hepatitis C patients with the NS3/4A
protease inhibitor danoprevir  (ITMN-191/RG7227) leads to robust reductions in
viral RNA: A phase 1b multiple  ascending dose study
PSI-7977  and BMS-790052 interferon-free trial for Geno 1,2 and
3 initiated
Victrelis  (boceprevir) and Incivek (telaprevir) transcript; FDA
May 23, 2011  Teleconference Briefing on Direct Acting
Antivirals
Telomerase  mutations are genetic risk factors for cirrhosis

Predictors of  spontaneous HCV clearance in HIV-infected
men
Hepatitis  C News; Its All About Incivek/Telaprevir

Discovery Of Canine  Hepatitis C Virus Opens Up New Doors For
Research On Deadly Human
  Pathogen


05-2011
FDA  Oversight Of J&J Is ‘Deeply Troubling’
FDA approves Telaprevir / INCIVEK For The  Treatment Of
Hepatitis C
FDA  OKs Telaprevir for Hep C; Financial Assistance/Prescribing
Information
Second Drug Wins Approval For Treatment of
Hepatitis C
Merck  has included Victrelis/Boceprevir to its patient
assistance program/May 22
New ; 2011 Dermatologic disorders and  liver disease
Merck's  Hepatitis C drug wins approval in
Europe
Positive  48-week Interim Data from TMC435 Hepatitis C Phase 2b
ASPIRE Study in  Treatment-Experienced Genotype-1 Patients
U.S. requests seizure of adulterated
cheese products at Wisconsin  company
Finally, Progress Against a Silent Killer;
Brand New Treatment for  Hepatitis C Increases Importance of Getting
Tested
From U.S. Centers for Disease Control  and Prevention

May 20, 2011
"Last week, the US Department of Health  and Human Services,
along with members of Congress, unveiled a detailed action  plan for dealing
with America's epidemic of viral hepatitis. And Friday marked  the beginning of
a new era for the treatment of hepatitis C: The [Food  and Drug Administration] gave
the green light to adding protease inhibitors  to the current treatment
regimen.
JX594/TG6006  Randomized Phase 2 Clinical Data Shows Promising
Survival Benefit In Patients  With Advanced Liver Cancer
The Next Step Toward  New Therapies - Predicting The Fate Of
Personalized Cells
A Senate Bill To Unseal  Secret Pharma Documents

You can read the text of Senate Bill 623 here.
Medical  Journal Ads And Unsubstantiated Claims

World  Hepatitis Day May 19 2011, Causes, Events, Activities,
Seminars
Higher  Rebates and Discounts Have Greater Influence on
Reimbursement Status for  Hepatitis C Therapies
Statin Use and the Risk of  Liver Cancer: A Population-Based
Case-Control Study - pdf attached
Impact of IL28B  polymorphisms on response to peginterferon and
ribavirin in HIV-hepatitis C  virus-coinfected patients with prior nonresponse
or relapse - pdf attached -
Hepatitis C
therapies
Danoprevir- Improvement in Insulin  Sensitivity With Protease Inhibitors in
Genotype 1 HCV
EU  Revises API Certification Policy
Now, the European Directorate for the Quality of
Medicines and  Healthcare (EDQM) has clarified the appeal process .

FAIR  PRICING COALITION EXPRESSES DISMAY AT THE PRICE OF MERCK’S
NEWLY APPROVED  HEPATITIS C DRUG
10 Totally Cool and  Incredibly Useful Medical Gadgets and
Apps
State  AIDS Drug Programs Have Huge Waiting Lists

Vitamin D  Linked to HIV Disease Progression
Getting  Ready; Telaprevir or Boceprevir ?
Diabetes
conveys a  higher risk of gastric cancer mortality
Breaking  the silence about depression among men

Staying  Safe During a Hospital Stay
Merck Strikes First in Hep C Drug
Battle
VICTRELIS/Boceprevir  FDA Approved:Now What? A Guide For
Patients
VICTRELIS™- Boceprevir: Prescribing Information and Medication
Guide
Hep-C cluster sparks concern

Telaprevir Improved Outcomes for Hep C
Patients Who Failed Prior  Therapy
May 14
Washington Week: Medicare Funds, New HCV
Drug Top Busy  Week
HHS  Launches Action Plan to Target Hepatitis
(CME/CE)
Lab Notes: Traveling  Backwards and Catching Viruses

Vicrelis/Boceprevir  IS NOW FDA Approved May 13 2011

elaprevir Ups Response  Rates Across IL28B Genotypes in
Hepatitis C
HHS Announces Action  Plan To Prevent And Treat Viral
Hepatitis
Can-Fite Announces A  Promising Interim Analysis Data Of Its
Phase I/II Liver Cancer Study With The  CF102 Drug
DDW:
Rifaximin Cuts  Peritonitis in Cirrhosis
Adult Stem Cells Take Root In Livers  And Repair
Damage
Darunavir Recalled Due to
Contamination
DDW;Video New Hepatitis C Drugs Come  With A
Warning
DDW:  Study Backs HCV Screens for All
Boomers
Bed  Bugs Are Biting And Spreading
Resistant Super Bacteria MRSA
Institute develops traditional medicine
against hepatitis C
HIV Physicians Are Cautiously Optimistic
About Boceprevir,  Telaprevir For HIV-HCV Co-Infected
Patients
Part Two; New Video On Hepatitis C By Vertex
Digestive  Disease Week® (DDW) 2011 Liver Meeting May 7-10,
2011
Genetic variation associated with response
to hepatitis C therapy  in HIV co-infected patients
Will there ever be an Aids
vaccine?
Vertex drug has a new
name
http://hepatitiscnewdrugs.blogspot.com/2011/05/update-telaprevirvertex-plans-us-phase.html

Painkillers need clearer warnings to
prevent liver  damage
Viral hepatitis: Mechanism of fatigue in
patients with chronic  hepatitis C involves carnitine
New two part videoTreating with  boceprevir and
telaprevir
May is Hepatitis Awareness
Month
FDA rule could rock supplement
industry
A  Lone "Wolf" Descends -- Declares Telaprevir the Presumptive
Winner
WHO  Warns of Enormous Burden of Chronic
Disease
Application Of Nanotechnology –
Nanoparticles Breakthrough  Expected To Aid In Early Detection Of Any
Cancer
New Drugs For Hepatitis C: Part 1 –
Boceprevir And  Telaprevir
New  Drugs For Hepatitis C: Part 2 – Boceprevir And Telaprevir
Dosing Regimens And  Side EffectsMuch anticipated hepatitis C drug 'highly
effective'
FDA Staff Sees Only Minor Issues for
Telaprevir
Hepatitis  C News; Boceprevir Wins Favorable FDA Staff
Review
Boosted  ABT-450 Improves Early Response to Interferon for
Hepatitis C
Idera  Delays Study of TLR9 Agonist IMO-2125 for Hepatitis
C
On The Blog

04-2011
Vitamin E or metformin may not be
effective for treating liver  disease in children and teens
Vertex, Merck Step Up to the Public Stage
With Hepatitis C Drugs  This Week
FDA's boceprevir review spotlights safety
concerns
On the verge of its first blockbuster
drug, can Vertex transform  itself into a money-making
enterprise?
Many Malaysians are 'walking time bombs'
Study examines transmitted HIV drug
resistance in Asia
The New York Times:
A Fight
Over How Drugs Are Pitched
Promising medical news

Vaccine for Hepatitis C
Liver-Cell  Transplants Show Promise In Reversing Genetic
Disease Affecting Liver And  Lungs
Genetics  of hepatitis C linked hepatocellular
carcinoma
erck- Boceprevir, Vertex-Telaprevir Prep for Hep C Drug
Panels
FDA  Panel Is Set To Review Two New Hepatitis C
Drugs
In The News April 20th;
Menopause,Oysters,Antidepressants,Acai  Berry and More
Jennerex  and Green Cross Announce Publication of Positive
Clinical Data of JX-594 in  Combination With Sorafenib in Advanced Liver
Cancer
Stage 4 Liver Cancer Symptomse
information covered in the  given article will help you know more about stage 4
liver cancer symptoms.
European Gastroenterologists Will
Prescribe Telaprevir and  Boceprevir to Nonresponder and Treatment-Naive
Patients Following Launch
Medicinal Marijuana: No easy
high
Monday  Hepatitis C In The News; HIV Vaccine As Distant
Goal,Marijuana,Diabetes,HCV Geno  1 and More
Prime-Boost  Vaccine Against Hepatitis C: CInovio,Transgene
& ChronTech Pharma  collaborate
Hepatitis  C: IL28B test Launced by AccuType® to physicians and
for clinical trials  research
Treating  Hepatitis C: That Was Then, This is
Now
Sould  Patients with Abnormal Liver Function Tests in Primary
Care be Tested for  Chronic Viral Hepatitis
New Hepatitis &  Tattos
Blog
FDA  Urged To Ban Diet Pill Over Liver Damage
Boceprevir, Telaprevir to  Usher in New Era of HCV
Therapy
High Viral Response Rates Seen  With Boceprevir for
HCV
EASL: Anemia & TelaprevirVideo-Chronic  fatigue syndrome:Potential causes and current
research April 2011Inflammation  of the Liver
HIV/AIDS-like  symptoms; UNDIAGNOSED DEBILITATING ILLNESS -
CHINA
More  evidence links diabetes, Parkinson's
disease
Doctors  overusing thyroid cancer treatment:
study
VA  patients, adults, now children at risk for contracting
HCV/HBV/HIV in a medical  setting
Vertex Receives Good News on Hepatitis C
Treatment
Medical Edge: Hepatitis C

Doctors  Are Losing Faith In Johnson &
Johnson
Interferon Lambda Beats  Interferon Alfa-2a for HCV
InfectionTelaprevir Add-On Effective  After Initial HCV Therapy
Fails
Updates at NATAP
BI 201335 pharmacokinetics and  early effect on viral load in
HCV genotype-1 patients
SVR and pharmacokinetics of  the HCV protease inhibitor BI
201335 with PegIFN/RBV in HCV genotype-1 patients  with compensated liver
cirrhosis and non-response to previous PegIFN/RBV -
Inhibitex  Reports Positive Safety and Antiviral Data from Its
Phase 1b Study of HCV  Nucleotide Inhibitor INX-189
No
resistance to IDX184 was  detected in 3-day and 14-day clinical studies of
IDX184 in genotype 1-infected  HCV subjects -
Idenix NS5A HCV replication  inhibitors with low picomolar,
pan-genotypicin vitro antiviral activity
CHARACTERIZATION OF NOVEL,  HIGHLY POTENT NS5A INHIBITORS WITH
QD DOSING POTENTIAL AND ROBUST ACTIVITY IN AN  HCV CHIMERIC ANIMAL MODEL

GNS-227:
A New Potent and  Selective (2nd Gen) HCV NS3 Protease Inhibitor With a High
Genetic Barrier to  Resistance -
ACH-2928: A NOVEL HIGHLY  POTENT HCV NS5A INHIBITOR WITH
FAVORABLE PRECLINICAL CHARACTERISTICS -
PHARMACOKINETICS,  PHARMACODYNAMICS, SAFETY AND TOLERABILITY OF
ACH-1625 (HCV NS3 PROTEASE  INHIBITOR) IN HCV GENOTYPE 1 INFECTION -

CHARACTERIZATION
AND  IDENTIFICATION OF PPI-437, PPI-668 AND PPI-833 AS POTENT AND SELECTIVE HCV
NS5A  INHIBITORS WITH ACTIVITY AGAINST ALL HCV GENOTYPES -
Updated; Digest Of Over 140 Hepatitis Clinical
  Trials
Hepatitis C  "HALT-C" Increased mortality rates seen with
pre-cirrhotic advanced  fibrosis
Triple drug regimen wipes out hepatitis
C
Addition of one drug  does trick
rish team  identifies hep C risk
factors
Summary of  investigational  Hepatitis C drugs presented at this
months EASL
Hepatitis  C In The News For April 5; Mericitabine (formerly
RG7128)
Early hep C drug pricing spooks
experts
More  On Tainted Wipes;U.S. marshals seize materials at
company
FDA
FDA  released a new, user-friendly search page for
consumers who have any concerns  about  recalls
Cholesterol Regulator Plays Key Role in
Development of Liver  Scarring, Cirrhosis
Bristol-Myers  Interferon-Free Combo And 4-Drug Combo Impressive
"BMS-650032/BMS-790052" Plus  SOC
Drug-resistant  variants emerge in most patients who fail to
achieve SVR with telaprevir-based  regimen
Telaprevir  Combo Works for HCV Patients with Prior Treatment
FailureBoceprevir  Improves Response to Interferon-Based HCV
TherapyBoceprevir  Helps Hepatitis C Patients with
Cirrhosis
Better  Then SOC; Improvements in Viral Cure Rates
W-Telaprevir-Based TX Regardless of  IL28B Genotype Status
Boceprevir;  Four-Week Lead-In Response and IL28B Status Helped
Define Likelihood of  Achieving SVR
Sustained Viral  Response Achieved In 83% Of Hepatitis C
Infected Patients With New HCV Protease  Inhibitor From Boehringer
Ingelheim
Telaprevir-Based  Regimens Prove Significantly More Effective
Compared To Current Standard Of Care  In Treatment- Experienced Hepatitis C
Patients
EASL;  Presidio's PPI-461, a novel HCV NS5A inhibitor
preliminary results
Achillion  ACH-1625 hepatitis drug shows promise in mid-stage
trial
EASL  Telaprevir Improved SVR Rates in People Whose Prior
Treatment For Hepatitis C  Was Unsuccessful
EASL;  DEB025 achieved SVR in 76% of patients with chronic
hepatitis C
Nine  Dead, Tainted IV Nutrition Solution
ImplicatedFirst European-Wide  Research Confirms Benefits Of
D-Penicillamine And Trientine For Wilson  Disease
First Vaccine
for Viral Hepatitis C Could Become a Reality
EASL;  Fluvastatin Enhances Chronic Hepatitis C Treatment
Response In Combination With  Pegylated Interferon-Alpha And
Ribavirin
The Importance Of  Policy Action To Support Efforts To Reduce
HCV-Related Deaths Across Europe By  2025
Report,  Hearing Focus on Disease
Clusters
Boceprevir  New England Journal of Medicine.
Boceprevir for  Untreated Chronic HCV Genotype 1
Infection
Boceprevir for  Previously Treated Chronic HCV Genotype 1
InfectionA  Better Way to Unbind Prometheus? Boceprevir for the Treatment
of Chronic  Hepatitis C InfectionBoceprevir;  Difficult Hepatitis C Type Responds to Novel
Protease Inhibitor
Boceprevir Effective  for Hepatitis C Virus Infection


03-2011
EASL;  Presidio's PPI-461, a novel HCV NS5A inhibitor
preliminary results
Achillion  ACH-1625 hepatitis drug shows promise in mid-stage
trial
Acupuncture can  spread serious diseases:
Full story: Canada.com
Hall  Of Shame; Pharmaceutical Companies and HCV oh
my!
tStem  cells to fat cells: Researchers uncover signal that helps
control process
Interventional  Radiology Y-90 Liver Cancer-busting Treatment:
Safe, Fast, Extends  Life
Nordion Reports  TheraSphere® Phase II Clinical Trial Results At
Society Of Interventional  Radiology
Gene  Regulation Mechanism Promotes Liver
Cancer
Hepatitis  B Treatment Improves Liver Disease in HIV/HBV
Coinfected
Revitalize with spring;Secrets for
longevity
The European Union  (EU) Launches The EU
Clinical Trials Register 
CAM/drug Interactions  Put Cancer Patients At Risk,
Australia
Interns  at the Operating TableSimplified Explanation of the  Phase 3 Studies of HCV Protease
Inhibitor Boceprevir -
New  Perspectives on Cancer and the Immune
System
Rep. Turner calls for hearings on VA
safety practices
What Is A  Parasite? What Do Parasites Do?
OraSure
Technologies  Submits CLIA Waiver Application For OraQuick(R) Hepatitis C Virus
Rapid  Test
Regimens:  Drug Is Seen to Limit Progression to
Diabetes
Hepatitis;  PSI-938 and PSI-7977 Breaking Down The Media
Frenzy

H&P  Industries, the parent company of the Triad
Group, has issued a voluntary recall  of all lots of providine idodine prep
pads
March 19 2011
A few months ago  the HCV community was alerted to a
recall of prep pads from the Triad group.  Some of these alcohol prep pads
manufactured by H&P, triads parent company,  were packaged with pegasys in
the U.S . and Pegintron outside the U.S. Back in  February these pads from
H&P were potentially contaminated with a rare  bacteria, Bacillus cereus.

MSNBC had this story; USA: FDA knew of problems with Triad's
tainted alcohol  wipes.
New Recall: All lots of povidine iodine
prep pads manufactured by  H&P Industries Inc.
As of March 15th H&P
Industries, the parent  company of the Triad Group, has issued a voluntary
recall of all lots of  providine idodine prep pads. The notice from H&P
stated the pads may be  contaminated with "Elizabethkingia meningoseptica", an
organism that has caused  rare but serious infections in humans, including,
pneumonia in patients on  ventilators and necrotizing fasciitis, more commonly
known as flesh-eating bA  and meningitis in newborn infants. As noted in the
press release from H&P  now on the FDA's website the new recalled
prep pads include povidine  iodine prep pads made by H&P Industries packaged
under the names Cardinal  Health, Medical Specialties, VHA, Triad, Triad Plus,
North Safety and Total  Resources.
Update March 29th-----
Hepatitis  C; FDA asks maker of tainted wipes to stop
production

Summary from CROI for  Hepatitis Coinfection - New drugs for
treatment of hepatitis C are becoming  available: what does that mean for the
HIV coinfected patient? -
HCV Infection and  the Incidence of CKD (pdf attached)
-
The
Effect of Low-dose  Ritonavir on the Pharmacokinetics of the Investigational HCV
Protease Inhibitor  Telaprevir in Healthy Volunteers
Miami-Dade congressional leaders toured
the Miami VA hospital  where vets got flawed colonoscopies
Nevada  doctor blames license flap on
manufacturer
101  patients of Las Vegas doctor told to get
tested
When  A Clinical Trial Goes Awry, ‘Fire The
Nurse!’
Hepatitis  News; In Focus Complementary and Alternative
Medicine
In  liver-disease patients, cognitive impairment may not be
fully reversible
Bristol-Myers  Squibb accused of bribing pharmacists and doctors
with kickbacks
Hepatitis;  U.S. Patent granted for ACH-1625 and Related
Protease Inhibitors
Soon, localized delivery of anti-cancer
drug by remote-controlled  microcarriers
Big  Day For Hepatitis C News; Monday Mar 14th 2011
BI  201335;BILB 1941 Boehringer Ingelheim HCV Portfolio to Be
Presented at  EASL
Hepatitis  C vaccine; Inovio partner ChronTech Pharma begins
phase 2 trial
(RG7128)  and danoprevir; Australians Hepatitis C treatment
breakthrough
Hepatitis  C Cirrhosis; Vitamin K Deficiencies
Definition,  Epidemiology, and Etiology of
Cirrhosis
Hepatitis  Foundation International Educates Medical Students
About Liver Health
Can  an Aspirin a Day Keep Cancer Away?
Pharmasset to Challenge Vertex Hepatitis C
Treatment, BMO  Says
Hepatitis  C Drug Telaprevir and VX-222 Accepted For
Presentation at EASL
Peregrine's Bavituximab HCV  Abstract Accepted for Presentation
at the 46th Annual Meeting of EASL
Hepatitis  C: IMO-2125 Data will be presented at
EASL
Hepatitis  C Drug BMS-790052 and BMS-650032 to be Presented at
The International Liver  Congress 2011
Hepatitis  C Drug;Boceprevir will be presented at The
International Liver Congress
TM/  46th European Association for the Study
ofthe Liver (EASL)
Hepatitis  C Drug IDX184 will be presented at The International
Liver Congress/ 46th  European Association for the Study of the Liver
(EASL)
Headache? Joint Pain? How to Choose the
Right Over-the-Counter  Painkiller
Simultaneous Occurrence of  Pleural Effusion and Interstitial
Pneumonitis After Treatment With Pegylated  Interferon for Hepatitis C Virus
Infection
Was pulmonary toxicity induced  by interferon therapy?

Southern Medical Journal, March 2011
Abstract and  IntroductionCase Report
Discussion
Conclusion
Telaprevir  works well for people with
HIV/HCV coinfection
Diabetes can takes six years off your life
by increasing risk of  cardiovascular disease and cancer, study
says
Liver  disease neglected in diabetes
Three  died in one week after organs from same
donor
Gallstones  Tied to Earlier Death
IL28B  Genotyping : Scripps Pioneers Individualized Medicine
by Offering Genetic  Testing to Hepatitis C Patients
Individualized Therapies
Now Available for  Drug Treatment of Hepatitis
C

02-2011News  Digest

Coverage From NATAP

Reported by Jules Levin
The 21st  Conference of the Asian Pacific
Association for the Study of the LiverAPASL Feb  17-20, 2011 Bangkok,
Thailand
APASL: Can HCV
Be Cured Without  Peg/RBV: Combination BMS-790052, BMS-650032 and pegIFN/RBV
Provides Undetectable  HCV RNA Through 12 Weeks of Therapy in HCV Genotype 1
Null Responders -
APASL: Direct-Acting Antiviral  Therapy for Hepatitis C: Attitudes
Regarding Future Use -
Download the PDF  here
APASL: Phase 2 Study of Pegylated  Interferon Lambda for HCV: Safety,
Viral Response, and Impact of Host Genotype  Through Week 12
-

Redesign of US donor-liver network could
boost transplants by  several hundred per year
Hepatitis  C treatment
Warning issued to Fuzeon, Pegasys,  Viraferon Peg and Intron A
users
The US Food and Drug Administration has  issued a warning to
users of four injectable drugs that may be used by people  with HIV and/or
hepatitis C regarding microbial contamination of alcohol
Hepatitis  C News;Recalled Alcohol Prep Pads possibly linked to
the death of a  child
Antiviral Activity of  Boceprevir Monotherapy inTreatment-Naive
Subjects With Chronic Hepatitis C  Genotype 2/3
Burden of Viral Hepatitis C in  Japan: A Propensity Analysis of
Patient Outcomes
Immunosuppressants Benefit Children With
Liver Failure
Abstract
Full Text (subscription or payment may be
required)
Medivir  - The Phase 3 Program for TMC435 in Treatment-Naive
Patients and Patients who  Have Relapsed After Prior Interferon-Based Treatment
has Now  Started.
IL28B Genotyping :Scripps Pioneers Individualized Medicine
by Offering Genetic  Testing to Hepatitis C Patients
Individualized Therapies
Now Available for  Drug Treatment of Hepatitis C
Vaccine  Technology Protects Against Hepatitis C Virus in Mouse
Model
Prebiotics,  probiotics and synbiotics improve minimal
hepatic encephalopathy
Personalized Medicine Comes Within
Reach
UPDATE 2-FDA removes full clinical hold on
Idenix's HCV  drug
Label  Mix-Up Prompts Recalls of Two Medications


Feb. 17, 2011 /PRNewswire/ -- Conatus
Pharmaceuticals Inc.  announced today the treatment of the first patient in a
multi-center Phase 2b  clinical trial evaluating CTS-1027 in combination with
Peginterferon Alfa-2a  (Pegasys®) and ribavirin (Copegus®) in a treatment
experienced, hepatitis C  (HCV) null responder patient population.


New York: Patients Treated at Rockland
Psychiatric Center Warned  of Hepatitis Risk
Caramel Coloring in Soda: What
You Should Know About This  Innocent-Sounding Ingredient
High  bilirubin levels within normal range linked with reduced
risk of respiratory  diseases
Parents  blame toddler's death on tainted alcohol wipes

Pharmaceuticals has  become aware of a broad United States
market recall of alcohol prep pads, swabs  and swabsticks manufactured by the
Triad Group and marketed under various brand  names.
Parents  blame toddler's death on tainted alcohol wipes

New  hepatitis C drug
Inhibitex Receives Fast Track
Designation for INX-189  for the Treatment of Chronic Hepatitis C
Infections
Treatment  of Recurrent Hepatitis C after Liver
Transplantation
Tenofovir  Remains Effective against Hepatitis B Virus after 5
Years in HIV/HBV Coinfected  Patients
Chronic  Fatigue Syndrome:ME/CFS
Cirrhosis Patients at  Increased Risk of Extrahepatic
Cancer
Defence issues warning on steroid
abuse
10,000 Hepatitis C  Patients Could Hold The Key To Better
TreatmentHCV New Drug Research: Hepatitis C;
FibroTest is a validated  non-invasive marker of fibrosis
UC Davis scientists successfully
bioengineer functioning liver  tissue
Hepatitis  C Daily News; Telaprevir Feb 2 2011
Dr.  House and The Undiagnosed Diseases Program
Vertex "Telaprevir" Urges CDC to  Recommend Hep C Screening, To
Nudge “Second Tsunami” of Patients.
Predicting  The Spread Of Cancer From The Level Of Tumor
Protein
The Daily Checkup: Liver cancer is on the
rise but early  screenings & treatment offer hope
Link Between Specific  Populations Of Gut Bacteria And Fatty
Liver
Hepatitis C; A Forced Legacy
Liver,  Dietary Proteins Key In Fertility
2011 Hepatitis C Drugs Telaprevir and
Boceprevir: I'm Still  Waiting
Research  into reprogrammed stem cells: an interactive
timeline
HCV New Drug Research: Hepatitis HIV :
Veterans Call For VA  Medical Center To Shut Down In St.
Louis

01-2011 News  Digest
Medications for
sleep in liver disease
Weekend  Hepatitis C News Jan 22
The  News: Hepatitis C Jan 21
EHSI Forms Joint  Venture To Develop Stem-Cell Treatment For
Liver Disease
Hepatitis In The  News
Adult Stem Cells Treat End-Stage Liver
Disease
Starting  Hepatitis C Treatment: Tips and
Information
Top  U.S. Hospitals and A Story
InThe  News; Liver Health/Hepatitis C Compensations and
More
Monday  Hepatitis C News Updates Jan 31
New  mouse model paves the way for the development of hep C
vaccines
Anadys Initiates  Dosing in Phase IIb Study of
ANA598
http://www.anadyspharma.com
Hepatitis News:Gene  that protect patients
with hepatitis C virus (HCV) against anemia brought on by  antiviral
treatment
Henderson doctor linked to 8 deaths says board bowed to
political  pressure
Drugmaker  Vertex moving to Fan Pier
Merck  Says Hepatitis B Vaccine Safe; Unrelated to TG Swab
Recall
New "Soda Pot"  Flavors Entering California Medical Marijuana
Market

HEP C  Newsletter;
January 2011
HCV
Advocate;
Top  10 News Items of 2010
Top  10 News of 2010HealthWise:  Vitamin D and the Liver
HCV  Snapshots
AASLD  2010: Part 2
Top Ten  News Stories about Hepatitis
B
New York Magazine Top  Infectious Disease Doctors in NYC

HIV and  Hepatitis Top Ten For 2010
Surgery Tech Asks Court To Reduce Sentence

Scientists grow  human liver tissue to be used for
transplantation
Mark your calendars, Fools:  May is going to be a solid month
for drug approvals.
Locals Warned Of  Chemical-Laden Drinking
Water
People  with HIV have high stroke risk: US
study
Liver  Disease and Vitamin B 12
Hepatitis  C News : Infections Canada's 'silent
epidemic'
Cell  Transplantation Reports A Success In Treating End-Stage
Liver Disease
Liver  Health: Deep vein thrombosis (DVT) In
Cirrhosis
Hepatitis  C And Liver News Of The Day Jan 17th
Fatty  liver: 70% to 90% of people with obesity or diabetes
develop fatty  liver.
Pharmaceutical  Gossip : Hall Of Shame
Liver  toxicity warnings: FDA limits acetaminophen in
prescription combination  products
Hepatitis  B : Safety of Tenofovir
Hepatitis  C:New direct-acting antivirals'
combination/2011
Anemia  during Hepatitis C Treatment Predicts Sustained Response
to Pegylated  Interferon/ribavirinHepatitis  B Therapeutic Vaccine Appears Safe and Stimulates
Immune Response
CV  Safety Risks Found for All NSAIDs
Peregrine Initiates Randomized Phase II
Trial of Bavituximab in  Chronic Hepatitis C Open-Label Trial Evaluating 12
Weeks of Therapy With Novel  Targeted Antibody Bavituximab in Combination With
Ribavirin Versus Standard of  Care
Liver Disease A  Possible Predictor Of Stroke:
Study
Bristol-Myers Squibb and Pharmasset Enter
into a Clinical  Collaboration Agreement for Proof of Concept Combination Study
in Patients  Chronically Infected with Hepatitis C
Social Class And  Changes In Mortality From Liver Cirrhosis Over
The 20th Century
Contaminated blood  compensation 'an insult'
Shoppers exposed to hep A at
Wal-Mart

12-2010
Hepatitis  C News: 01-07Hepatitis  News: Investigated Fort Detrick Concern For High
Liver Cancer Rates
Jan  4th
Dangers  of Toxoplasma Parasites: Harmful W-Suppressed Immune
Systems
Hepatitis In The News: Jan  3rd
Video:  IL28B gene and hepatitis c treatment
Blood  Test To Spot Cancer Gets Big Boost from Johnson &
Johnson
Lower  Recurrence Rate for HCC Treated With
Resection
Organ  Harvesting In China
Halted  Part Of Telaprevir/VX-222 Study
20% of
American adults have some degree  of fatty liver disease
Health  authorities warn against dangerous oral
supplement
"Warning  Miracle Mineral Solution: ITS BACK"
Nonalcoholic  Fatty Liver Disease Linked to Idiopathic Venous
Thromboembolism
Lilly, other big drugmakers shut out by
FDA in 2010
MELD score is fair  to patients waiting
for liver re-transplant: study
Vertex  gears up for its big year
Hepatitis/Liver:NASA  Developed Stem Cell Technology in
China
Birmingham leads stem cell trial on
damaged livers
ISSCR Website For  Patients:
Patient  Handbook on Stem Cell Therapies
Guidelines for the Clinical Translation of Stem
Cells
NEW
"ISSCR" Website
Debating  Key Concepts in HCV Management With New HCV
Therapies
Scripps Research scientists  identify key
interaction in hepatitis C virus
Low-dose ribavirin helpful in  HCV and
thalassemia
Cells' Natural  Defence Against Cancer-Causing Viruses
Discovered
With Flu And Cold  Season In Full Swing, The American Public
Health Association Encourages Proper  Hand-Washing
Plasma Therapy, An  Alternative To Antibiotics?
Ocera
Therapeutics  Completes First In Human Studies With OCR-002 For The Treatment Of
  Hyperammonemia And Hepatic Encephalopathy
Delcath Submits CE  Mark Technical File For Hepatic ChemoSAT™
Delivery System
Can’t Get No Respect: Why Investors
Punished Gilead for a Drug  That Halts HIV
HBV Genotype A  Carries Higher Viral
Titers Than Other Genotypes
Achillion To Present Data From Studies Of
ACH-1625 In Hepatitis C  At Asian Pacific Liver Conference
Hepatitis  B: The Real Killer Is Silence
Half  of those diagnosed with chronic Hepatitis B are Asian
Americans and Pacific  Islanders, and most were infected Research  Fuels Hope for Hard-To-Treat Hepatitis C Patients
Hepatitis C pouncing on Boomers at
midlife
AASLD  2010 Conference – Part 1
IL28B  Gene Highlighted at AASLD
HealthWise:  2010 Liver Meeting UpdateHCV  SnapshotsHepatitis  C: When Pharmaceutical Companies Behave
Badly
Hepatitis  News: Roche Demands VN To Stop Making
InterferonSimilar  progression of fibrosis between HIV/HCV co–infected and
HCV–infected  patients
Hepatitis  News: This and That On Sunday
Is IL28B Testing A  Threat To Telaprevir Or To Patients
?
New therapy uses body's  own 'killer cells' to attack liver
cancer
Patients  with cancer,Hepatitis C,HIV/AIDS can buy 2.5 ounces of
marijuana every two  weeks
Amarillo  Biosciences Announces Completion of Patient Enrollment
in Phase 2 Hepatitis C  Trial
Hepatitis  Experts Accelerating the Development of Targeted
Therapies
Patient  Voices: Hepatitis
Hepatitis.Hepatitis  C Trial Drug PSI-7977:Pharmasset explores shorter
treatment durations in naive  Geno 2 and 3
Benitec Limited (ASX:BLT) Granted Another
RNA Interference Patent  In Europe Providing Further Support For The Hepatitis C
Program
Hepatitis researchers face FIA
probe
Potential  new treatments for hepatitis B, tuberculosis
underway
CDC:  Flu Outbreak in Georgia Signifies Start of Flu
Season
Podcast:Fake  Drugs & Fake Stem Cell
Websites
First U.S. Patient Treated with the  Accu2i Percutaneous
Microwave Tissue Ablation Device (pMTA).
Virologic Response Protects Against Death
in Liver Transplant  Patients With HCV
Hepatitis  C News In The Morning Dec 07
Diagnostic accuracy of  FibroScan and comparison to liver
fibrosis biomarkers in chronic viral  hepatitis: A multicenter prospective study
(the FIBROSTIC study) - published pdf  attached -
Hepatitis C pouncing on Boomers at
midlife
Risk Of Death  Increases In IBD Patients With Hospital-Acquired
Infections
Hepatitis  C : Morning News
Todays  News Dec 2 : Hepatitis
Anemia  And Other Side Effects During TreatmentHepatitis  C Best Of The Liver Meeting
Hepatitis C Vaccine Elicits Immune
Response in Some  Patients
Pharmasset Initiates  Dosing In A Combination Study Of PSI-7977
And PSI-938 For Chronic Hepatitis  C
Ikaria® Begins  Enrollment Of Pivotal Trial For
LUCASSIN®
Scoring System Is 93%  Accurate For Diagnosing Wilson's Disease
In Pediatric Patients
Concerns  HIV cases going unreported in NT
High  Court to rule on hepatitis compensation
case
Decreased  levels of microRNA miR-122 in individuals with
hepatitis C...
Interim  Results Show TMC435 Works Well in Treatment-experienced
Hepatitis C  Patients
Sticking Fast To Foil  Hepatitis C
Liver  Cancer: Video Understanding SIR-Spheres microspheres -
Whats Being Discussed  ?
Pharmasset Initiates Dosing  in a Combination Study of PSI-7977
and PSI-938 for Chronic Hepatitis CHepatitis  C December Newsletter: IL28B Gene
Highlighted

11-2010 News
Digest
Hepatitis scandal a call to
arms
Irreversible inhibition of a  protease central to hepatitis C
infection; New HCV Protease AVL-192: Study (full  text; published pdf
attached) - 11/29/10
AASLD: New HCV Drugs at AASLD - 11/29/10
AASLD:
Assessment of Hepatitis C  Virus Attitudes Towards Treatment
Among Methadone Maintenance Treatment Program  Staff -
11/29/10
AASLD: Ultra-Deep Sequencing of the  NS3 and NS5B Regions Detects
Pre-Existing Resistant Variants to Direct Acting  Antivirals (DAA) in HCV
Genotype 1 Treatment-Naïve Infected Patients -11/29/10
Nov  2010 Telaprevir® Vertex Competes FDA Application; Asking
for “Fast  Track”
Unexpected elevated alanine
aminotransferase, asparte  aminotransferase levels and hepatitis E virus
infection among persons who work  with pigs in Accra, Ghana.
Apricus, FDA agree on liver cancer drug
study
Hepatitis  C News Nov 21: Murder in Your Hospital ?
HRSA Awards $1.6  Million To Improve Availability And Expansion
Of Hepatitis C (HCV)  Treatment
Combination Therapy  Improves Survival Time For Patients With
Advanced Liver Cancer
TMC435  positive interim data on Phase 2b ASPIRE study for
HCV
AHA:  Docs Don't Discuss Drug Interactions
Top Hospital Organ  Transplant Centers Identified By
HealthGrades
USC Study Finds That  Hispanic Children Are Genetically
Predisposed To Developing Fatty Liver  Disease
News
From The Journal  Of Clinical Investigation: Nov. 15, 2010
Further Analysis of Vacc-4x Phase IIb  Study Shows a
Statistically Significant Reduction in Viral Load Over Placebo -- Previous
Decision to Put Vacc-4x on Hold Has Been Reversed -- .
.
Hepatitis  C Therapeutics Market in Malaysia -
Compound  That Blocks Sugar Pathway Slows Cancer Cell
Growth
Cleveland Clinic  offers free health
tips
Liver Transplantation Linked to
Accelerated Cellular  Aging
Partial Liver Transplantation and Native
Organ  Regeneration
Arizona  Budget Cuts Put Some Organ Transplants Out of
Reach.
Blockbuster  Vaccines of the
Future
AZT  not linked to worsening anaemia in patients starting ART in
Uganda
Occult  Hepatitis B Infection in Egyptian Chronic Hepatitis C
patients: Prevalence,  impact on Pegylated Interferon/Ribavirin
therapy
Hepatitis  C In The News Nov 15 2010
AASLD: The Wall Street Journal
Reports
Curing  Hepatitis C Will Take More Than New
Treatments
Studies  Assess Genes in Ribavirin-Induced
Anemia
Roche  Two Fines/One For Pegasys:Monies Paid To Nurse/Health
Service To Use  Drug
AASLD: Men Make  Better Liver Donors
AASLD: Human  Cells Grow on Animal Liver
Scaffolds10/31/2010
Donor
Race May Impact  Recurrent Hepatitis C In Liver Transplant
Patients
From The TheStreet
Strides Against Hepatitis C Open Door to
  Blockbusters


10-2010
Race Affects Hepatitis C Recurrence After
Liver Transplant:  Study
Hepatitis  C Virus Causes Brain Inflammation Leading to Neuron
Injury
Small  Livers Grown In A Laboratory From
Human Liver Cells
Pharmasset Announces Results  of a 28-day Phase 2a Study with
PSI-7977 for the Treatment of Chronic Hepatitis  C Infection
Biolex
Announces Locteron  SVR12 Results and Safety/Tolerability Advantages in SELECT-2
Hepatitis C Trial
Boceprevir,Telaprevir Faster Cure For
Hepatitis C
October  2010 HCV Advocate.

In This Issue:REALIZE  Top-Line Resultsl
HCV
Advocate. New Fact Sheets .
Boceprevir
Telaprevir .
DISABILITY & BENEFITS: Life Settlements (Cash for Your Life
Insurance  Policy)
HealthWise:  Finding Safety in Numbers
HCV  Snapshots
lSVR  Reduces Risk of Death and Disease
Spice
In Curry Could  Prevent Liver Damage
ACG: Obesity Linked  to Noncirrhotic Liver
Cancer
Expert Panel Of  Pediatric Liver Specialists Establishes
National Recommendations For The  Treatment Of Children With Chronic Hepatitis B
Infections
Olive Oil Protects  Liver
Pain  May Predict Liver Cancer
Prognosis
Hepatitis  C Drugs and Wall Street
Hepatitis  C And The CDC
Telaprevir® Vertex To File FDA Application “Within
Weeks”*
HCV:  A New Drug Enterprise For The Convicted Sam Waksal
?
Vertex;VX-222  and Telaprevir, Vertex disclosed rebound in viral
load in phase IIb  study
Vertex  Pharmaceuticals Announces Start of a Phase 3b Study of
Twice-Daily Telaprevir in  People Not Treated Previously for Hepatitis
C
Some Liver  Cancer Patients May Benefit From Personalized
Treatment
Quick  Study; FAQ SVR Rates Treating With
Telaprevir
Vienna Intl AIDS Conference  Thoughts from Jules Levin, NATAP
. ..
Direct-acting  Drugs Danoprevir plus RG7128 Suppress HCV without
Interferon
HIV/HCV  Coinfected Women More Likely than Men to Modify or
Discontinue Hepatitis C  Treatment
Police  raid doctor's home
NH  Man Indicted for Attempted Liver Transplant
Scam
Video/Bronx  Girl, 3, May Have HIV After Needle
Accident
stem-cell  based neurological, liver therapy strategies
advanced
Personalized treatment may  help some liver cancer
patients
Homo  musculus: Researchers Create a "Humanized" Mouse for Liver
Disease  Studies Prison  Drug Treatment Programs May Get Axed in Budget
Battle
New  Virus 'Jumps' From Monkey to Scientist, Causing Serious
Illness
Looking Into  Pharmas
HCV  Morning News Oct 20th
U.S. Food and Drug
Administration Approves  BARACLUDE® (entecavir) as a Treatment for Chronic
Hepatitis B Patients with  Evidence of Decompensated Liver Disease ;l
HCV,HBV,HIV  and Liver Cancer Around The World
Silymarin  Milk Thistle Extract May Inhibit Hepatitis C Virus
Entry into Cells
Mystery Virus Still  Keeping
Secrets
Fatty  Liver Disease, Genotype 3, Vitamin E and HCV

Stem  Cells/Producing Liver Cells presented at
AASLD
Hepatitis  C Virus Attacks Brain
Cells
Hepatitis C Drugs Rated By Consumer
Reports
Terrence Higgins  Trust Launches Group For Gay Men With
Hepatitis C And HIV, UK
Experts Rally To Get  European Commitment To Halting The
Hepatitis B And C Epidemic
Mayo Clinic Finds  Early Success With Laser That Destroys Tumors
With Heat
ScScientists Link  Hepatitis C Virus Infection To Fat Enzyme In
Liver Cells
New  European Study Shows TheraSphere(R) Prolongs Liver Cancer
Survival  Rates
Nutrition Studies  Explore Health Benefits Of Fish
Hospital Fined  After Health Worker Infected With Hepatitis C,
UK
Human Genome  Sciences Receives Complete Response Letter From
FDA On ZALBIN™ BLA For Chronic  Hepatitis C
Data Monitoring Committee Unanimously
Recommends Continuation  Of Celsion's Phase III ThermoDox® HEAT Study To Treat
Primary Liver  Cancer


09-2010 News DigestHepatitis C Fear and  Loathing, Biopsy vs.
Fibro scan in NZ
Roche Says Roche TaqScreen DPX Test  For
Parvovirus B19 And Hepatitis ...
Full story:  Stock Market
Review
Development  of Two HCV Experimental Drugs Halted
September 27, 2010
Jefferson Starts Live  Donor Liver Program
FDA
Guidance for Development of Directing-acting  Antiviral Drugs for Hepatitis
C
See Draft Guidance :FDA

New Credit Rating: Vertex  Pharmaceuticals
Johnson &
Johnson CEO: 'We made a mistake'
Practical  Chronic Hepatitis Snacking
Tips
Bed  Bugs and HCV, HIV and HBV
HCV/OTHER MEDICAL
PROBLEMS
c-Met May Be A  Biomarker For Metastatic Hepatocellular
Carcinoma
Research Could  Improve Detection Of Liver
Damage
After Liver  Transplantation, Faith In God Associated With
Improved Survival
Data Monitoring  Committee Unanimously Recommends Continuation
Of Celsion's Phase III ThermoDox® HEAT Study To Treat Primary Liver
Cancer
HCV  Outside the Body: How Well Does It Survive on Surfaces, in
Syringes, and in the  Lab?
Hep C may benefit from genetic  fingerprinting, research
says
IMO-2125  New HCV Drugs/AASLD Oct/2010Three-quarters of People with Hepatitis C
in the U.S. Have  Hard-to-treat Genotype 1
Weight-based  Taribavirin Works as Well as Ribavirin for Chronic
Hepatitis C, but Causes Less  Anemia
Chocolate  Intake, Depression, and Clinical Progression in
HIV-HCV...
Roche Receives FDA  Approval For Second-Generation Hepatitis B
Viral Load Test
Cell Division  Typically Associated With Cancer May Also Protect
The Liver From  Injury
Taribavirin Offers A  Safe, Effective Alternative For Chronic
Hepatitis C
Virologic response rates of  weight-based taribavirin versus
ribavirin in treatment-naive patients with  genotype 1 chronic hepatitis C

The
Next Step for Taribavirin  - Commentary
Launch  of Novel Agents for the Treatment of Hepatitis C Virus
Will Precipitate  Treatment of At Least Half of 'Warehoused'
Patients
Wall  Street Journal Article on Hepatitis C
200th NICE Technology  Appraisal Guidance To Help Tackle Growing
Hepatitis C  Problem
Appraisal Guidance To  Help Tackle Growing Hepatitis C
Problem
Only 10 percent liver transplants  on female patients:
Doctors
Full  story: Newkerala.com"Wall Street is bracing for one of the
biggest new drug categories  in a decade: the launch of a series of antiviral
medicines that could  dramatically improve the cure rate for hepatitis
C"
Concerns About  HCV Genotyping: Hepatitis
C Virus (HCV) Genotype 1 Subtype Identification in New  HCV Drug Development and
Future Clinical PracticeThe NHS regulator, NICE, has updated
guidance on the treatment of  hepatitis C. This covers the use of peginterferon
alfa (2a or 2b) and ribavirin  for the treatment of chronic hepatitis C
This
new guidance reflects changes  in licensing and recommends their wider use and,
where appropriate, shorter  treatments for adults with the disease.

Safety
and Pharmacokinetics  of BMS-650032 Following Multiple Ascending Doses for 14
Days in Healthy Subjects
Telaprevir  Combination Therapy Boosts Sustained Response Rates
for Previously Treated  Hepatitis C Patients
FDA  Suspends Trials of Experimental HCV Regimen IDX184 plus
IDX320 Due to Liver  Toxicity Concerns
Week 4  Rapid Virological Response Predicts Sustained Response
to Interferon-based  Hepatitis C Treatment